Sodium-glucose cotransporter 2 inhibitors (SGLT2i), or gliflozins, are antidiabetic agents primarily approved by the US Food and Drug Administration to treat type 2 diabetes (T2D) since 2013.1,2 SGLT2i have also been shown to improve outcomes among patients with chronic kidney disease, heart failure, and coronary artery disease.1,3,4,5,6,7,8,9,10,11,12. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.